Abstract Superparamagnetic iron oxide-based contrast agents enhance and complement in vivo magnetic resonance imaging (MRI) by shortening T2 and T2* relaxation times. They are able to highlight areas of cellular inflammation, being detected and engulfed by cells of the reticuloendothelial system, and can be targeted to specific cellular processes or subtypes using antibody or ligand labeling. These agents have been used preclinically for the assessment of cardiac transplant rejection, cardiomyocyte apoptosis, myocardial infarction, myocarditis, and stem and endothelial cell imaging, with clinical applications now emerging. We here review recent studies using iron oxide particles to image cardiac inflammation, and highlight the potential of these agents for future clinical and research applications.
Introduction

Overview of Iron Oxide Nanoparticles
In many inflammatory diseases of the myocardium, endomyocardial biopsy is the 'gold standard' diagnostic investigation. However, this does carry the potential for lifethreatening complications [1] , and false negative or inconclusive results are not uncommon due to the focal nature and spatial heterogeneity of the underlying inflammatory disease process. Development of a reliable noninvasive imaging technique capable of detecting myocardial inflammation would be extremely beneficial and a major advance. This could provide a diagnosis in patients displaying early signs suggestive of myocardial inflammation or with subclinical disease, creating an opportunity to prevent the disease process from become established or limit its progression. Furthermore, this could provide a surrogate measure of treatment response and facilitate serial disease monitoring.
Iron oxide nanoparticles can be used for molecular and cellular imaging [2] , and thereby enhance the sensitivity of magnetic resonance imaging (MRI) to detect and characterize various pathologic processes [3] . They rely on the principle that accumulation of superparamagnetic iron oxide particles within tissues causes local magnetic field inhomogeneities that shorten T2 and T2* relaxation times. They generally consist of an iron oxide core surrounded by a carbohydrate or polymer coat that prevents aggregation and oxidation of the iron, and provides a surface for conjugation of drug molecules and targeting ligands. A range of particles exists and they vary in size and coating. These 2 properties of iron nanoparticles are the key determinants of their biodistribution, magnetic behavior and, thus, the potential applications of the particle [4, 5] .
Iron oxide particles can be categorized according to their size (Table 1) : nano-sized very small (VSPIO, <20 nm in diameter), ultrasmall (USPIO, 20-50 nm in diameter) and small (SPIO, 60-250 nm in diameter) superparamagnetic particles of iron oxide, and micrometer-sized (MPIO, 1-8 μm in diameter) particles of iron oxide. The 'superparamagnetic' particles become magnetic within a strong external magnetic field such as exists within an MRI scanner, but do not retain their magnetism once removed from the field.
Iron oxide particles were initially used as contrast agents for imaging of the gastrointestinal tract [6] , the Kupffer cells of the liver and spleen [7] , and lymph nodes [8] , as well as a blood-pool contrast agent for the evaluation of cerebral, myocardial, and renal perfusion [9] [10] [11] . Here, we focus on its application to image cardiac inflammation with an emphasis on recent findings, and comment on future applications.
USPIO and VSPIO
The VSPIO particle is the smallest of the iron particles and the USPIO particle is only slightly larger; hence, these agents are often classified together as USPIO. Their clinical application makes use of their ability to escape immediate phagocytosis by cells of the reticuloendothelial system, conferring a considerably longer half-life within the blood pool (up to 24 hours [12] ) compared with larger particles. Both VSPIO and USPIO have been used successfully as contrast agents for MR coronary angiography [13, 14] because they have a longer blood pool circulating time compared with standard MR angiographic agents such as Gadolinium. Although USPIO remain predominantly within the blood pool, they are small enough to migrate passively across the endothelium [2] especially in regions of the vasculature where there is loss of endothelial integrity. Once present within tissues, resident macrophages with enhanced phagocytic activity engulf and concentrate these nanoparticles. This colocalization and concentration of nanoparticles enhances their superparamagnetic effects markedly shortening the T2* value and creating local signal deficits that appear dark on T2-and T2*-weighted images (Fig. 1) . It is these magnetic effects of USPIO that allow their use to detect capillary leakiness and tissue-resident inflammatory cell activity, thereby highlighting areas of tissue inflammation.
SPIO
SPIOs are larger than USPIOs, and as such are more rapidly phagocytosed by cells of the reticuloendothelial system in the liver, spleen, bone marrow, and lymph nodes (Fig. 2) . They are rapidly cleared from the blood pool after injection having a short blood pool half-life of less than 15 minutes [15] in rats and around 2 hours in humans [16] . After intracellular uptake, SPIOs are degraded into a nonsuperparamagnetic form of iron that becomes incorporated into the body's iron stores [2] . The coating of the particle also has to be metabolized, and coating with dextran confers the advantage that it is biodegradable and excreted in urine and feces [17] .
MPIO
The largest of the iron particles discussed, MPIOs, are often used for molecular imaging of endovascular targets. As a result of their large size MPIOs have a very short blood pool half-life of <1 minute in mice [18] and <2 minutes in rats [19] . Following intravenous administration phagocytic cells within the blood pool and the lymphoreticular system identify them rapidly. However, until they are cleared, they are less susceptible than smaller particles to migrate across endovascular borders or be incorporated into endothelial cells, and are confined to the intravascular compartment [20] . For this reason, MPIOs are often used to provide a platform for quantitative targeted molecular imaging of vascular endothelial targets. By labeling cells ex vivo with MPIO, single cell detection has been shown in vivo [21] . Importantly, MPIO contain significantly more iron oxide than USPIO or SPIO and consequently fewer MPIO are required for detection. Indeed, they create such an effect on local magnetic field homogeneity that the spatial extent of the change in signal intensity on T2-and T2*-weighted imaging can be up to 50 times its own physical diameter. This so-called "blooming effect" markedly enhances sensitivity such that MPIOs can detect even sparse endothelial molecular targets [22] , but spatial information may be compromised. Imaging Using Iron Particles
Early preclinical imaging work took advantage of the ability of inflammatory cells of the reticuloendothelial system to engulf iron particles enabling the iron particles to act as a tracer localizing to areas of inflammation. Cardiac pathologies examined include cardiac transplantation, cardiomyocyte apoptosis, myocardial infarction (MI), and myocarditis. The use of iron particles has also been employed to examine cellular apoptosis and tracking of stem cells. Histologic validation is important and tissue can be stained with Prussian Blue or Perl's stain for iron ( Fig. 3 ) and colocalization can be confirmed if the same tissue is subsequently stained for inflammatory cells such as macrophages (CD68 immunohistochemistry).
Cardiac Transplant Rejection
Cardiac transplantation is a major treatment option for endstage cardiac disease, but is challenged by the development of transplant rejection in 20 %-30 % of recipients in the first year [23] . This causes significant morbidity and mortality. Transplant rejection can occur at any stage after transplantation and is notoriously difficult to diagnose noninvasively. It is characterized histologically using the International Society for Heart and Lung Transplantation (ISHLT) classification system and graded into 1 of 3 groups depending on the presence of interstitial and perivascular mononuclear cell infiltrates, myocyte damage, edema, hemorrhage, or vasculitis [24] . Endomyocardial biopsy is undertaken routinely for rejection surveillance following transplantation, although this procedure can be associated with serious complications that include damage to the underlying cardiac structure, bleeding, arrhythmia, and death [1] . Kanno et al. [25] detected organ rejection using MRI and dextran-coated USPIO in rats with evidence of cardiac allograft rejection. Histopathology not only confirmed active rejection, but also confirmed UPSIO uptake was confined to tissue-resident macrophages that accumulated within the rejecting cardiac allograft. Interestingly, in rats that had more prolonged immunosuppression, they also 3 Perl's iron stain of the aortic wall from a patient with an abdominal aortic aneurysm. Tissue sample was acquired during operative repair 4 days following the administration of USPIO. USPIO is seen to have accumulated within macrophages in an inflamed region of the tunica media observed a decline in the rate of signal intensity reduction, suggesting less inflammation and indicating that successful treatment response could also be monitored by this method.
Wu et al. [26] studied a rat model of heart-lung transplant rejection involving the implantation of an additional intraabdominal heart and lung allowing the native heart to support life despite severe rejection in the transplanted organs. USPIO was administered 1 week following transplantation. One day after USPIO administration, hypointense areas appeared on T2*-weighted images of allograft hearts that were not present within the control native hearts and immediate histology after graft explantation revealed accumulation of iron particles mostly within macrophages.
Targeting of various pathophysiological processes of interest becomes possible when contrast agents, including iron oxide particles, are conjugated to a specific antibody or peptide [12] . Recent work by Guo et al. [27•] targeted T cells that play a central role in acute rejection in most cardiac allografts. They built on work performed using ligand targeting of cells to employ a "theranostic" strategy, combining diagnostic imaging with administration of therapy within the 1 system. They targeted T cells in the endocardium of abdominally implanted rejecting rat hearts using a CD-3 antibody-targeted multifunctional polymeric nanocarrier. This polyplex nanoparticle was further conjugated to a therapy gene (pDNADGKalpha) enabling simultaneous imaging of primary T cells expressing CD-3 and achieving their immune modulation via gene therapy.
Cardiomyocyte Apoptosis
Apoptosis is the process of programmed cell death in an organism and in the myocardium confers a survival advantage to the organism over necrosis, which induces inflammation and leads to scarring. During apoptosis the phospholipid phosphatidylserine is exteriorized and displayed on the cell surface. Annexin V is an endogenous protein that binds with high affinity to phosphatidylserine. Narula et al. [28] Technetium-labelled Annexin V binding was observed in 5 out of the 18 human patients with cardiac allografts. All 5 of these patients displayed at least moderate rejection histologically and demonstrated caspase-3 staining, a marker for apoptosis. In contrast, none of the 13 patients with no annexin uptake displayed histologic signs of necrosis.
Dash et al. [29] developed a molecular MRI probe using SPIO conjugated to recombinant human Annexin V (ANX-SPIO). Using T2*-weighted MRI, they were able to detect doxorubicin-induced early apoptosis in mouse hearts in vivo. There was a spatial correlation between areas of signal attenuation on T2*-weighted images and histologic evidence of iron accumulation and apoptosis (caspase activity), although myocardial structure was normal suggesting only early apoptosis. They were also able to detect apoptosis in cultured ex vivo neonatal rat ventricular myocytes much earlier than TUNEL staining: the latter detects DNA fragmentation and is a late terminal event in the apoptotic sequence. Perhaps more importantly, they were able to use ANX-SPIO to demonstrate that the alpha-1 adrenoreceptor agonist, A61603, could prevent doxorubicin-induced cardiomyopathy. They documented early apoptosis through increased caspase activation and reduction in myocardial T2* value that could be eliminated by A61603 treatment.
The development of cross-linked particles of iron oxide (CLIO) [30] was exploited for targeted imaging of apoptosis again conjugated to annexin V [31] . Cross-linking and amination of the USPIO dextran chains encourages circumferential adherence of the dextran coat to the iron nanoparticle providing chemical stability and improved conjugation [30] . This allowed Sosnovik et al. [32] to develop a CLIO particle conjugated not only to annexin V, but also to cyanine 5.5 dye to allow co-identification with fluorescence microscopy and T2*-weighted MRI. In a murine model of ischemia reperfusion injury, a reduction in signal intensity on T2*-weighted imaging was observed with AnxCLIO-Cy5.5 but not with unlabeled CLIO-Cy5.5. The area of signal loss correlated with the zone of contractile dysfunction suggesting uptake of AnxCLIO-Cy5.5 was within the injured and apoptotic myocardium. This was further confirmed by near infra-red fluorescence where increased fluorescence intensity co-localized to regions of reduced signal intensity on MRI.
More recently, Sosnovik et al. employed a similar concept in developing a novel dual-contrast molecular MRI technique to image both cardiomyocyte apoptosis and necrosis in mice with ischemia reperfusion injury in vivo [33] . They used a similar protocol to identify apoptosis and followed this with injection of a novel magnetofluorescent gadolinium chelate (Gd-DTPA-NBD), with subsequent gadolinium delayed enhancement MRI. Interestingly, they found that only 21 % of apoptotic myocardium (accumulation of AnxCLIO5.5) had evidence of necrosis (defined by delayed enhancement with Gd-DTPA-NBD). This was confirmed on fluorescence microscopy and immunohistochemistry revealing the presence of large numbers of apoptotic, but potentially viable, cardiomyocytes in the 'at-risk' area (AnxCLIO-Cy5.5 positive, Gd-DTPA-NBD negative areas). The authors concluded by remarking that strategies to salvage apoptotic, but not yet necrotic, myocardium should be explored now that these areas could be successfully imaged.
Myocardial Infarction
Yang et al. [18] imaged inflammatory cell infiltration in a murine left anterior descending coronary artery ligation model of myocardial infarction. Micrometer-sized particles of iron oxide (MPIO) were administered and T2* signal attenuation was seen in the infarct zone of these mice when compared with control groups of mice that (I) were administered MPIO and had a "sham' operation, or (II) were subjected to MI but did not receive MPIO. Unsurprisingly, they noted increased signal attenuation in the infarct area, illustrating MPIO accumulation secondary to increased inflammatory cell infiltration. This correlated functionally with a reduction in left ventricular ejection fraction.
In a subsequent study by the same group [34] , they explored the dose and timing of MPIO administration and MRI scanning. The investigators concluded that an optimal temporal scanning window of 7-14 days post-MI, and an optimal dose of 9.1-14.5 μg of iron per gram bodyweight to image myocardial inflammation.
Alam et al. [35••] used USPIO to image inflammation dynamics following acute myocardial infarction (MI).
Within 48 hours following acute MI, patients received an infusion of ferumoxytol (USPIO) and underwent MRI scanning at baseline (pre-USPIO) and for 3 days. The infarct zone was defined using a late gadolinium enhancement (LGE) scan. Following USPIO administration, there was a significant increase in R2* (R2*=1/T2*) in the infarct zone, with smaller changes observed in the peri-infarct zone (surrounding LGE) and even in remote myocardium when compared with control tissue (skeletal muscle). The authors suggested that this was a reflection of peri-infarct and remote myocardial inflammation, although there were no histologic data to confirm this. Notably, the R2* value was greatest 24 hours following USPIO (ferumoxytol) infusion, and had declined by 48 hours suggesting that 24 hours postinfusion is the most sensitive imaging time point in this group of patients.
In a similar study, Yilmaz et al. [36• •] also detected a reduction in T2* value in the infarct as well as in the periinfarct region, the remote myocardium and the lymphoreticular system. In imaging the first 3 patients at 6, 24, 48, and 96 hours after ferumoxytol administration, they attempted to find the optimal time to characterize inflammation kinetics within the myocardium. From these data, they suggest that signal attenuation was maximal at 24 hours but that the best combination of T2-weighted (hypoenhancement seen) and T2*-weighted images were obtained at 48 hours.
Unfortunately, neither Yilmaz nor Alam had access to histologic samples. Such data would address the outstanding questions regarding the exact distribution of USPIO within the myocardium, and the potential contribution to the changes in T2* or R2* of extracellular iron accumulation within the interstitium, capillary bed, or tissue resident macrophages.
The finding of T2* signal void in remote myocardium in the above articles is an interesting observation suggesting a pan-myocardial inflammatory response in the context of a smaller, highly localized infarct. This finding is in agreement with Grieve et al. [37] who used a rat model of ischemiareperfusion injury, and examined endovascular inflammation using a targeted MPIO tracer. They found MPIO signal in the myocardium and pericardium in segments remote from the ischemia-reperfusion injury. In a mouse model of myocardial infarction, remote inflammation after myocardial infarction has also been demonstrated [38] . An increase in inflammatory mediators was found not only within the remote myocardium, but also within renal glomeruli suggesting that inflammation is not only confined to the myocardium, but extends to distal sites and tissues.
Myocarditis
Transplant rejection and myocardial infarction are not the only inflammatory myocardial processes to be scrutinized by molecular imaging employing iron particles. Like transplant rejection, myocarditis suffers from the lack of a reliable noninvasive diagnostic test, and again patients are subjected to the risk of biopsy procedures that have a lower diagnostic sensitivity than clinicians would wish.
Moon et al. [39] recently examined a rat model of experimental autoimmune myocarditis. They made use of superparamagnetic and fluorescent "magneto-fluorescent nanoparticles" (MNPs) consisting of a SPIO core with a rhodamine isothiocyanate (RITC)-incorporated silica coating of approximately 20 nm thickness, and polyethylene glycol (PEG) conjugated onto the silica coating. They compared MNP (10 mg Fe/kg) contrast MRI with unenhanced conventional MRI protocols using T2-weighted, T1-weighted and early and late gadolinium enhancement sequences. The degree of inflammation was also assessed histologically. MNPenhanced T2*-weighted CMR more accurately detected scattered foci of inflammation within the myocardium of rats with autoimmune myocarditis and improved visualization of small and less-severe myocardial inflammation than conventional CMR imaging. Areas detected by MNP-enhanced T2*-weighted CMR correlated with inflammatory foci and macrophage accumulation on histology as well as MNP-derived fluorescence signals on fluorescence microscopy. However, MNP-enhanced MRI ultimately proved unable to detect mild histologic grades of myocardial inflammation, and this may limit its clinical applicability.
Stem Cells
Current research endeavors are increasingly focusing on stem cell therapy in an attempt to restore function to organs that were previously felt to have no or little regenerative capacity. There is, therefore, a clear need to track stem cells when administered for therapeutic and regenerative purposes so that the distribution and fate of administered cells can be determined. Kraitchman et al. [40] labeled mesenchymal stem cells (MSC) with SPIO in order to detect and track them noninvasively using MRI in a swine model of myocardial infarction. Labeling did not appear to affect the viability of the MSCs, and hypointense regions were seen on MRI within infarcted myocardium after intramyocardial SPIO-MSC injection, suggesting uptake of the SPIO-MSC conjugate.
Lu et al. [41] recently investigated the effects of culprit vessel intracoronary infusion of SPIO-labeled autologous bone marrow-derived MSCs after acute myocardial infarction in pigs. One-week postmyocardial infarction SPIO-labeled MSCs were infused via the culprit coronary vessel and compared with a control infusion of phosphate-buffer saline. The pigs were imaged immediately before and 3 days after cell transplantation. A reduction in myocardial T2* value was observed after cell transplantation in the study group compared with the control group. However, the majority of the infused cells were found in the spleen, liver, and kidney, resulting in a more pronounced reduction in T2* values in those organs. Immunohistochemistry confirmed this to be the SPIO-MSC conjugate, suggesting the majority of the infused cells escaped into the systemic circulation. There was no difference seen between groups in terms of global or regional cardiac function or myocardial viability although the followup in this group was too short to see any functional recovery. The authors acknowledge a weakness of this method is that signal may be "diluted" if the stem cells subsequently proliferate. Furthermore, this cell tracking method could create misleading results. Although not demonstrated by this study, the iron nanoparticle could become detached from the stem cell allowing it to be taken up by another cell, or left behind in the tissue.
In a murine model of myocardial infarction, Chung et al. [42• ] studied cell viability and teratoma formation after embryonic stem cell (ESC) transplantation. They made use of a reporter gene designed to express antigens on the surface of embryonic stem cells (ESCs). By employing SPIOconjugated targeted monoclonal antibody (SPIO-MAb) against these reporter antigens, the viability, proliferation, and teratoma formation of transplanted ESCs could be quantified in vivo with MRI. The advantage of this reporter gene technique over direct stem cell labeling, is that the signal is enhanced when the stem cell successfully divides, thus, allowing quantification of subsequent stem cell proliferation.
Endothelium
Although the majority of preclinical endothelial imaging using iron oxide has examined large vessel vascular endothelium, which is beyond the scope of this review, there has been some recent work in the heart. Dall'Armellina et al. [43] employed a targeted system in characterizing the role of vascular cell adhesion molecule-1 (VCAM) that is known to play a crucial role in promoting endothelial inflammation after ischemia-reperfusion injury [44] . They described T2*-weighted MRI signal drop out with antibody-conjugated MPIO targeting VCAM-1 in mouse hearts following coronary artery ligation.
Grieve et al. [37] followed this work by adopting a similar protocol conjugating MPIO with monoclonal VCAM antibodies in a rodent model of MI. Extensive foci of signal voids were observed within the infarcted area on ex vivo T2*-weighted MRI corresponding to MPIO deposition on histology. Supporting previous evidence of pan-myocardial inflammation after myocardial infarction, signal void was also detected in remote myocardium and pericardium.
Conclusion and Future Applications
Important and recent research has demonstrated that superparamagnetic particles of iron oxide can be used to detect cardiac inflammation in preclinical models of myocardial infarction, cardiac transplant rejection, myocarditis, as well as targeted imaging in stem cell therapy and apoptosis. These agents are able to provide a platform for both imaging and modulation of the disease process. Molecular MRI using iron nanoparticles, therefore, has the potential to develop into a powerful tool in diagnosing and treating inflammatory cardiac conditions in clinical medicine.
Recent translation of preclinical studies has already led to clinical applications examining myocardial inflammation following myocardial infarction. There have been concerns over the safety profile of iron oxide particles in the past, and at present there is only 1 iron oxide particle preparation available for clinical use: ferumoxytol (Rienso), a USPIO measuring 17-30 nm. Interestingly Rienso is indicated for the intravenous treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD), and not its imaging properties.
Previous clinical preparations of superparamagnetic particles of iron oxide have not had a particularly successful track record. Another USPIO, ferumoxtran-10 (Sinerem), was previously approved in some European countries, but the manufacturer discontinued development due to concerns over unacceptably high false positive rate of detecting lymph node metastasis in patients with prostate cancer [45] . Other iron oxide nanoparticles including NC100500 (Clariscan), ferumoxides (Feridex in USA, Endorem in Europe), and ferucarbotran (Resovist) have all been discontinued over recent years. The latter 2 agents were the only 2 clinically approved SPIO agents for MRI, and it remains to be seen whether commercial companies will consider it economically viable to develop further iron oxide based agents for human imaging.
The natural progression following limited clinical studies using ferumoxytol, would be to characterize kinetics and dynamics of inflammatory cell recruitment to the myocardium not only following MI but also in other inflammatory myocardial processes including cardiac transplant rejection, myocarditis, and active cardiac sarcoidosis. If iron nanoparticle-enhanced MRI was able to diagnose and characterize inflammation in these diseases, it may eventually replace the need for cardiac biopsy. In conjugating iron oxide to various peptide, antibody, or gene therapy platforms, a new method of targeted therapy is a further potential opportunity for the clinic. This novel imaging tool may therefore prove a useful platform not only for diagnostic and disease monitoring purposes, but may even provide a treatment approach in these conditions.
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